Table of Contents
Overview
United States
- Continued Criticism of Pharmaceutical Price Increases
- Preparations for Medicare Prescription Drug Benefit
- Employers' Response .
- Medicare Beneficiaries' Response
- Pharmaceutical Companies' Response
- Potential Savings from Greater Use of Generics
- Express Scripts Excludes Lipitor from Its Formulary
- Radical Reform of Florida's Medicaid Program
European Union
- Potentially Wider Application of Supplementary Protection Certificates
- Prospects for Pricing Reform
France
- Aggressive Cost-Cutting Program .
- Review of Reimbursement Status of Hundreds of Drugs
Germany
- Increased Pharmaceutical Spending Despite Lower Prices
- Potential for Substantial Savings on Medicines
- Government Plans for Stricter Cost-Containment
- More-Aggressive Reference Prices
- Price Freeze .
- Price Cuts on Off-Patent Medicines and an End to Rebates in Kind
- Daily Cost of Therapy Limits for Frequently Prescribed Medicines
- Impact of Reference Pricing
- Defeat for Pfizer in Court
- Manufacturer Rebates to Health Insurance Funds
Italy
- Modest Decrease in Pharmaceutical Spending
- Pharmacists Commit to Reducing the Cost of Medicines
Spain
- New Medicines Law Approved by Cabinet
- Call for Greater Transparency in Reimbursement Procedures
United Kingdom
- Patient Action Against Lack of Access to Certain Drugs
- Accelerated NICE Appraisal Process
- Expanded Prescribing Powers for Nurses and Pharmacists
Japan
- Industry Frustration over Proposed Pricing and Reimbursement Reforms
- Increasing Familiarity with Generic Drugs
Outlook and Implications for the Pharmaceutical Industry
| 
View Cart
